founders in biotech

Business development is an essential process for biotech companies to build relationships with partners and create value from the deal structures that are based on science. We are taking a deep dive with James Lee into the mechanics and the framework that James applies for business development. Youtube: https://lnkd.in/edV67ykk Listen on: Apple Podcast: https://apple.co/43Zn1Hj  Google Podcast: https://bit.ly/45opewX  Spotify: https://spoti.fi/3qqfBiB  Amazon Music: https://amzn.to/3DO2kn1 Visit our website: https://lnkd.in/emJjFCcT Thanks CSL for supporting this episode.  #biotech #innovation #inspiration #entrepreneur #Therapeutics

James Lee received his B.S and M.S. in Structural Biology from Seoul National University, he held various roles in research, research planning, and business development at LG Chem. In year 2000, James co-founded CrystalGenomics, Inc. where he led fundraising and business development activities. In 2008, he founded Rexbio, an early-stage biotech startup specialized in discovering and developing therapeutics and diagnostics for the treatment of pancreatic cancer.   James founded Bridge Biotherapeutics, Inc., Inc. in 2015 and he currently serves as the CEO. Bridge has been recognized with the continuous advancement of clinical-stage programs focused on pulmonary fibrosis, lung cancer, and immunology. In 2019, James successfully orchestrated the licensing-out deal with Boehringer Ingelheim, which marked as one of the largest global deals on a single compound in Korea. Listen Apple Podcast: https://apple.co/43Zn1Hj  Google Podcast: https://bit.ly/45opewX  Spotify: https://spoti.fi/3qqfBiB  Amazon Music: https://amzn.to/3DO2kn1 Watch Youtube: https://lnkd.in/efp9UMpm Thanks CSL for supporting this episode.  #biotech #innovation #inspiration #entrepreneur #Therapeutics #foundersinbiotech

Prof. Yaniv Erlich received his bachelor’s degree from Tel-Aviv University, Israel in 2006 and a PhD from the Watson School of Biological Sciences at Cold Spring Harbor Laboratory in 2010. Yaniv Erlich was an Associate Professor of Computer Science at Columbia University and was a PI at the Whitehead Institute, MIT. His research interests are computational human genetics. Yaniv has been an advisor for multiple companies in the area of genomics and bioinformatics. He authored over 40 peer-reviewed scientific studies, including multiple papers in Science, Nature Genetics, and Nature Methods. He holds five patents and has experience in both B2C and B2B in the area of genomics. Prof. Yaniv Erlich was the CSO of MyHeritage and currently he is the CEO of Eleven Therapeutics, a company that he co-founded in 2020. Eleven Therapeutics is a biotech company focused on development of groundbreaking RNA therapeutics. Host: Serghei Glinca Watch: Youtube: https://lnkd.in/eAh_uhVY Listen on: Apple Podcast: https://apple.co/43Zn1Hj Google Podcast: https://bit.ly/45opewX Spotify: https://spoti.fi/3qqfBiB Amazon Music: https://amzn.to/3DO2kn1 Visit our website: https://lnkd.in/emJjFCcT Thanks CSL for supporting this episode. #biotech #innovation #inspiration #entrepreneur #RNA #Therapeutics